Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Travere Therapeutics, Inc. (TVTX) provides access to the company’s official disclosures as a Nasdaq‑listed biopharmaceutical issuer focused on rare kidney, liver and metabolic diseases. Travere files periodic and current reports with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934.
Recent Form 8‑K filings document press releases announcing quarterly and preliminary annual financial results, including net product sales and other financial metrics, as well as broader corporate updates. These reports specify when information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and clarify that such information is not automatically incorporated by reference into registration statements unless expressly stated.
Travere also uses Form 8‑K to report material regulatory developments. For example, the company has filed 8‑Ks describing FDA communications on the supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS), including the decision that an advisory committee meeting was no longer needed and confirmation of the Prescription Drug User Fee Act (PDUFA) target action date. Another 8‑K notes the FDA’s extension of the review timeline after the company submitted additional information characterized as a Major Amendment.
Through this page, users can review Travere’s financial reporting (10‑K and 10‑Q when available), current reports on significant events (8‑K), and other disclosures that describe the company’s clinical programs, commercial activities, risk factors and capital structure. Stock Titan enhances these filings with AI‑powered summaries that highlight key points in lengthy documents, helping readers quickly understand topics such as revenue drivers, R&D spending, regulatory interactions and forward‑looking statements. Real‑time updates from EDGAR and access to insider and executive transaction reports, when filed on forms such as Form 4, allow investors to monitor how management actions and regulatory events intersect with Travere’s strategy in rare diseases.
Selected financial highlights (three and six months ended June 30, 2025): Total revenue was $114.4 million for Q2 and $196.2 million for the six months. Net product sales were $94.8 million in Q2 (FILSPARI $71.9M, tiopronin $23.0M) vs. $52.2M a year ago. License and collaboration revenue included a $17.5 million regulatory milestone. Operating loss for the quarter was $12.7M; six-month net loss was $53.98M (basic/diluted loss per share YTD $0.61). Cash and cash equivalents were $75.2M and available-for-sale marketable debt securities were $244.4M (total liquid investments $319.5M). Total assets were $555.3M, total liabilities $522.6M, and stockholders' equity $32.7M.
Operational and programmatic items: FILSPARI previously received full U.S. approval (Sept 5, 2024) and the European conditional MA converted to a standard MA in April 2025, triggering the $17.5M milestone in May 2025. The company submitted an sNDA seeking FSGS approval; the FDA accepted the sNDA and set a PDUFA date of Jan 13, 2026 and plans an advisory committee. Pegtibatinase enrollment is on a voluntary pause due to manufacturing scale-up issues. Renalys licensing and other collaborations remain active.